Nisa Investment Advisors LLC Boosts Stake in Gilead Sciences, Inc. $GILD

Nisa Investment Advisors LLC raised its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 362,516 shares of the biopharmaceutical company’s stock after buying an additional 16,947 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Gilead Sciences were worth $40,192,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in GILD. Price T Rowe Associates Inc. MD increased its holdings in Gilead Sciences by 314.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock valued at $1,647,484,000 after purchasing an additional 11,156,382 shares during the last quarter. Nuveen LLC purchased a new stake in shares of Gilead Sciences in the 1st quarter valued at $620,415,000. Kingstone Capital Partners Texas LLC purchased a new position in Gilead Sciences during the 2nd quarter valued at about $238,083,000. Los Angeles Capital Management LLC raised its holdings in shares of Gilead Sciences by 422.6% in the 1st quarter. Los Angeles Capital Management LLC now owns 2,523,036 shares of the biopharmaceutical company’s stock valued at $282,706,000 after purchasing an additional 2,040,261 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in Gilead Sciences by 1.7% during the first quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company’s stock worth $13,162,606,000 after purchasing an additional 1,942,433 shares in the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Stock Performance

Gilead Sciences stock opened at $120.94 on Friday. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. The stock has a 50 day moving average of $115.47 and a 200-day moving average of $111.07. The stock has a market cap of $150.06 billion, a P/E ratio of 24.09, a price-to-earnings-growth ratio of 0.83 and a beta of 0.34. Gilead Sciences, Inc. has a 52 week low of $86.08 and a 52 week high of $124.61.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.96 by $0.05. The company had revenue of $7.08 billion during the quarter, compared to analyst estimates of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm’s revenue for the quarter was up 1.4% compared to the same quarter last year. During the same period last year, the business earned $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, September 29th. Stockholders of record on Monday, September 15th were given a $0.79 dividend. This represents a $3.16 annualized dividend and a dividend yield of 2.6%. The ex-dividend date of this dividend was Monday, September 15th. Gilead Sciences’s dividend payout ratio (DPR) is 62.95%.

Analyst Ratings Changes

GILD has been the subject of a number of research reports. Dbs Bank upgraded shares of Gilead Sciences to a “moderate buy” rating in a research report on Friday, September 5th. Weiss Ratings reiterated a “buy (b)” rating on shares of Gilead Sciences in a research report on Saturday. TD Cowen lifted their price target on shares of Gilead Sciences from $115.00 to $125.00 and gave the company a “buy” rating in a report on Thursday. Truist Financial upgraded Gilead Sciences from a “hold” rating to a “buy” rating and upped their price objective for the stock from $108.00 to $127.00 in a report on Friday, August 8th. Finally, The Goldman Sachs Group boosted their price target on Gilead Sciences from $105.00 to $108.00 and gave the company a “neutral” rating in a research report on Friday, October 17th. One analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $122.61.

Insider Activity at Gilead Sciences

In other news, insider Johanna Mercier sold 3,000 shares of the stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total transaction of $354,240.00. Following the transaction, the insider owned 110,193 shares in the company, valued at $13,011,589.44. This represents a 2.65% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total transaction of $295,200.00. Following the transaction, the chief financial officer owned 157,055 shares in the company, valued at $18,545,054.40. This represents a 1.57% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 71,500 shares of company stock worth $8,281,540. 0.27% of the stock is owned by corporate insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.